Glaukos Corp

GKOS

Equity

ISIN US3773221029 / Valor 28262610

New York Stock Exchange, Inc (2024-11-21)

USD 140.83-0.43%

Glaukos Corp
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Glaukos Corp, founded in 1998, is an ophthalmic medical technology and pharmaceutical company that specializes in developing and commercializing innovative therapies for glaucoma, corneal disorders, and retinal diseases. The company is known for pioneering Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to traditional glaucoma treatments, with a portfolio of technologically distinct platforms aimed at advancing the standard of care in ophthalmology. Glaukos completed an initial public offering in 2015 and is listed on the New York Stock Exchange under the ticker symbol "GKOS". With global headquarters in Aliso Viejo, California, and additional locations in several countries, Glaukos is dedicated to providing better treatment options for patients worldwide.

Summarized from source with an LLMView SourceSector: Healthcare

Net Sales Growth

Glaukos Corp reported net sales of $82.4 million in the fourth quarter of 2023, marking a 16% increase on a reported basis compared to $71.2 million in the same period in 2022. On a constant currency basis, the increase was 15%.

Gross Margin

The gross margin for Glaukos Corp in the fourth quarter of 2023 was approximately 77%, slightly up from approximately 76% in the same period in 2022. The non-GAAP gross margin remained consistent at approximately 84% for both periods.

SG&A Expenses

Selling, general, and administrative (SG&A) expenses for Glaukos Corp in the fourth quarter of 2023 increased by 21% to $63.0 million, compared to $51.9 million in the same period in 2022. Non-GAAP SG&A expenses also saw a 22% increase to $62.3 million.

Net Loss

Glaukos Corp reported a net loss of $36.8 million, or ($0.75) per diluted share, in the fourth quarter of 2023, compared to a net loss of $31.5 million, or ($0.66) per diluted share, in the same period in 2022. The non-GAAP net loss was $30.6 million, or ($0.63) per diluted share.

2024 Revenue Guidance

Glaukos Corp has reaffirmed its 2024 net sales guidance, expecting revenue to be in the range of $350 million to $360 million based on the latest foreign currency exchange rates.

Summarized from source with an LLMView Source

Key figures

124%1Y

193%3Y

123%5Y

Performance

41.0%1Y

44.9%3Y

53.5%5Y

Volatility